{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T23:11:59Z","timestamp":1779923519249,"version":"3.53.1"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,30]],"date-time":"2024-04-30T00:00:00Z","timestamp":1714435200000},"content-version":"vor","delay-in-days":120,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.clinsp.2024.100381","type":"journal-article","created":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T08:58:46Z","timestamp":1715331526000},"page":"100381","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Noninvasive assessment of liver fibrosis can predict clinical outcomes at late follow-up after a sustained virological response in HCV patients?"],"prefix":"10.1016","volume":"79","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2703-082X","authenticated-orcid":false,"given":"Taisa Grotta","family":"Ragazzo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2444-7937","authenticated-orcid":false,"given":"Patricia Momoyo Yoshimura","family":"Zitelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2164-2630","authenticated-orcid":false,"given":"Daniel F.","family":"Mazo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2848-417X","authenticated-orcid":false,"given":"Claudia P.","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7682-3105","authenticated-orcid":false,"given":"Flait Jos\u00e9","family":"Carrilho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0942-7348","authenticated-orcid":false,"given":"M\u00e1rio Guimar\u00e3es","family":"Pessoa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinsp.2024.100381_bib0001","series-title":"WHO Draft Guidelines for Adverse Event Reporting and Learning Systems","year":"2021"},{"issue":"9","key":"10.1016\/j.clinsp.2024.100381_bib0002","article-title":"Impact of the COVID-19 pandemic on hepatitis B and C elimination: an EASL survey","volume":"4","author":"Kondili","year":"2022","journal-title":"JHEP Rep"},{"key":"10.1016\/j.clinsp.2024.100381_bib0003","unstructured":"World Health Organization. Hepatitis C: key Facts. 2021. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-c."},{"issue":"3","key":"10.1016\/j.clinsp.2024.100381_bib0004","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S2468-1253(16)30181-9","article-title":"Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study","volume":"2","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.clinsp.2024.100381_bib0005","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/S2468-1253(21)00472-6","article-title":"Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study","volume":"7","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.clinsp.2024.100381_bib0006","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1055\/s-0039-3399561","article-title":"Epidemiology of liver cancer in latin america: current and future trends","volume":"40","author":"Carrilho","year":"2020","journal-title":"Semin Liver Dis"},{"issue":"10","key":"10.1016\/j.clinsp.2024.100381_bib0007","first-page":"767","article-title":"Evolution of patients with chronic hepatitis C infection with advanced fibrosis or cirrhosis cured with direct-acting antivirals. Long-term follow-up","volume":"45","author":"Aranda","year":"2022","journal-title":"Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.clinsp.2024.100381_bib0008","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.jhep.2021.05.025","article-title":"EASL Clinical Practice Guidelines: non-invasive tests for evaluation of liver disease severity and prognosis \u20132021 update","volume":"75","year":"2021","journal-title":"J Hepatol"},{"issue":"6","key":"10.1016\/j.clinsp.2024.100381_bib0009","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.dld.2018.02.010","article-title":"Hepatocellular carcinoma risk assessment by the measurement of liver stiffness variations in HCV cirrhotics treated with direct acting antivirals","volume":"50","author":"Ravaioli","year":"2018","journal-title":"Dig Liver Dis"},{"issue":"3","key":"10.1016\/j.clinsp.2024.100381_bib0010","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/liv.13256","article-title":"Direct antiviral agent treatment of chronic hepatitis C results in rapid regression of transient elastography and fibrosis markers fibrosis-4 score and aspartate aminotransferase-platelet ratio index","volume":"37","author":"Bachofner","year":"2017","journal-title":"Liver Int"},{"key":"10.1016\/j.clinsp.2024.100381_bib0011","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/jvh.13416","article-title":"Altered balance between collagen formation and degradation after successful direct-acting antiviral therapy of chronic hepatitis C","volume":"28","author":"Laursen","year":"2021","journal-title":"J Viral Hepat"},{"issue":"5","key":"10.1016\/j.clinsp.2024.100381_bib0012","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/S0399-8320(07)89422-X","article-title":"Use of elastometry (fibroscan) for the non-invasive staging of liver fibrosis","volume":"31","author":"Castera","year":"2007","journal-title":"Gastroenterol Clin Biol"},{"key":"10.1016\/j.clinsp.2024.100381_bib0013","series-title":"Protocolo De Tratamento e Diretrizes Terap\u00eauticas (PCDT): Aten\u00e7\u00e3o Integral \u00e0s pessoas Com Infec\u00e7\u00f5es Sexualmente Transmiss\u00edveis (IST)","first-page":"119","author":"Sa\u00fade","year":"2015"},{"issue":"5","key":"10.1016\/j.clinsp.2024.100381_bib0014","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.2337\/diabetes.52.5.1210","article-title":"NCEP- defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older","volume":"52","author":"Alexander","year":"2003","journal-title":"Diabetes"},{"key":"10.1016\/j.clinsp.2024.100381_bib0015","series-title":"IBM-SPSS Statistics \u201328th Version [software]","year":"2023"},{"key":"10.1016\/j.clinsp.2024.100381_bib0016","series-title":"R Core Team. R: a Language and Environment For Statistical Computing [software]","author":"Chambers","year":"2015"},{"issue":"1","key":"10.1016\/j.clinsp.2024.100381_bib0017","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/hep.30866","article-title":"Diagnosis and treatment of alcohol-associated liver diseases: 2019 practice guidance from the American Association for the Study of Liver Diseases","volume":"71","author":"Crabb","year":"2020","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.clinsp.2024.100381_bib0018","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.gcb.2009.02.014","article-title":"Non-invasive diagnosis of liver fibrosis: guidelines for the use of biomarkers and Fibroscan","volume":"33","author":"Vergniol","year":"2009","journal-title":"Gastroenterol Clin Biol"},{"issue":"9","key":"10.1016\/j.clinsp.2024.100381_bib0019","doi-asserted-by":"crossref","first-page":"516","DOI":"10.6061\/clinics\/2017(09)01","article-title":"Accuracy of transient elastography-FibroScan\u00ae, acoustic radiation force impulse (ARFI) imaging, the enhanced liver fibrosis (ELF) test, APRI, and the FIB-4 index compared with liver biopsy in patients with chronic hepatitis C","volume":"72","author":"Ragazzo","year":"2017","journal-title":"Clinics (Sao Paulo)"},{"key":"10.1016\/j.clinsp.2024.100381_bib0020","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/8578051","article-title":"Restoring inflammatory mediator balance after sofosbuvir-induced viral clearance in patients with chronic hepatitis C","volume":"2018","author":"Saraiva","year":"2018","journal-title":"Mediat Inflamm"},{"issue":"1","key":"10.1016\/j.clinsp.2024.100381_bib0021","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/jvh.13204","article-title":"Time-dependent improvement of liver inflammation, fibrosis and metabolic liver function after successful direct-acting antiviral therapy of chronic hepatitis C","volume":"27","author":"Laursen","year":"2020","journal-title":"J Viral Hepat"},{"issue":"1","key":"10.1016\/j.clinsp.2024.100381_bib0022","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s12876-019-0973-5","article-title":"Rapid decline of noninvasive fibrosis index values in patients with hepatitis C receiving treatment with direct-acting antiviral agents","volume":"19","author":"Hsu","year":"2019","journal-title":"BMC Gastroenterol"},{"issue":"5","key":"10.1016\/j.clinsp.2024.100381_bib0023","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1053\/j.gastro.2019.07.033","article-title":"Increased risk for hepatocellular carcinoma persists up to 10 years after HCV eradication in patients with baseline cirrhosis or high FIB-4 scores","volume":"157","author":"Ioannou","year":"2019","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.clinsp.2024.100381_bib0024","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.cgh.2017.04.038","article-title":"Magnitude and kinetics of decrease in liver stiffness after antiviral therapy in patients with chronic hepatitis C: a systematic review and meta-analysis","volume":"16","author":"Singh","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"11","key":"10.1016\/j.clinsp.2024.100381_bib0025","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1111\/jvh.13587","article-title":"Non-invasive assessment of fibrosis regression and portal hypertension in patients with advanced chronic hepatitis C virus (HCV)-associated liver disease and sustained virologic response (SVR): 3 years follow-up of a prospective longitudinal study","volume":"28","author":"Knop","year":"2021","journal-title":"J Viral Hepat"},{"issue":"2","key":"10.1016\/j.clinsp.2024.100381_bib0026","doi-asserted-by":"crossref","first-page":"145","DOI":"10.15403\/jgld.2014.1121.262.dyn","article-title":"Dynamics of liver stiffness values by means of transient elastography in patients with HCV liver cirrhosis undergoing interferon free treatment","volume":"26","author":"Sporea","year":"2017","journal-title":"J Gastrointestin Liver Dis"},{"issue":"7","key":"10.1016\/j.clinsp.2024.100381_bib0027","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1080\/00365521.2021.1915374","article-title":"Evolution of liver stiffness and post-treatment surveillance by liver elastography for HCV patients in the DAA era","volume":"56","author":"Piecha","year":"2021","journal-title":"Scand J Gastroenterol"},{"issue":"11\u201312","key":"10.1016\/j.clinsp.2024.100381_bib0028","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1111\/apt.16092","article-title":"Fibroscan liver stiffness after anti-viral treatment for hepatitis C is independently associated with adverse outcomes","volume":"52","author":"Vutien","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.clinsp.2024.100381_bib0029","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1093\/cid\/cit234","article-title":"A risk for hepatocellular carcinoma persists long-term after sustained virologic response in patients with hepatitis C-associated liver cirrhosis","volume":"57","author":"Aleman","year":"2013","journal-title":"Clin Infect Dis"},{"issue":"24","key":"10.1016\/j.clinsp.2024.100381_bib0030","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1001\/jama.2012.144878","article-title":"Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis","volume":"308","author":"van der Meer","year":"2012","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.clinsp.2024.100381_bib0031","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1002\/hep.21492","article-title":"Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study","volume":"45","author":"Bruno","year":"2007","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.clinsp.2024.100381_bib0032","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.jhep.2009.12.028","article-title":"Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis","volume":"52","author":"Cardoso","year":"2010","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.clinsp.2024.100381_bib0033","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1053\/j.gastro.2017.06.012","article-title":"Risk of hepatocellular cancer in HCV patients treated with direct-acting antiviral agents","volume":"153","author":"Kanwal","year":"2017","journal-title":"Gastroenterology"},{"issue":"11","key":"10.1016\/j.clinsp.2024.100381_bib0034","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1016\/j.cgh.2020.02.044","article-title":"Disease progression in patients with hepatitis C virus infection treated with direct-acting antiviral agents","volume":"18","author":"Mendizabal","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"11","key":"10.1016\/j.clinsp.2024.100381_bib0035","doi-asserted-by":"crossref","first-page":"e00420","DOI":"10.14309\/ctg.0000000000000420","article-title":"Changing trends of cirrhotic and noncirrhotic hepatocellular carcinoma in the era of directly-acting antiviral agents","volume":"12","author":"Mathur","year":"2021","journal-title":"Clin Transl Gastroenterol"},{"issue":"2","key":"10.1016\/j.clinsp.2024.100381_bib0036","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1002\/hep.31060","article-title":"Hepatitis C guidance 2019 update: american Association for the Study of liver diseases-infectious diseases society of america recommendations for testing, managing, and treating hepatitis C virus infection","volume":"71","author":"Ghany","year":"2020","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.clinsp.2024.100381_bib0037","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1053\/j.gastro.2023.06.030","article-title":"Dynamics in liver stiffness measurements predict outcomes in advanced chronic liver disease","volume":"165","author":"Semmler","year":"2023","journal-title":"Gastroenterology"}],"container-title":["Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1807593224000589?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1807593224000589?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T04:23:09Z","timestamp":1735791789000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1807593224000589"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":37,"alternative-id":["S1807593224000589"],"URL":"https:\/\/doi.org\/10.1016\/j.clinsp.2024.100381","relation":{},"ISSN":["1807-5932"],"issn-type":[{"value":"1807-5932","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Noninvasive assessment of liver fibrosis can predict clinical outcomes at late follow-up after a sustained virological response in HCV patients?","name":"articletitle","label":"Article Title"},{"value":"Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinsp.2024.100381","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 HCFMUSP. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}],"article-number":"100381"}}